Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franck Bonnetain

Showing results (111-120 of 161) with videos related to

Pageof 17
Sort By:
International Journal of Cancer|July 30, 2016
Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological scoreMarine Jary, Thierry Lecomte, Olivier Bouché, et al.
American Journal of Clinical Oncology|April 8, 2009
Pilot study of transarterial chemoembolization with pirarubicin and amiodarone for unresectable hepatocellular carcinomaBoris Guiu, Cédric Colin, Jean-Pierre Cercueil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2011
Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapyAziz Zaanan, Jean-François Fléjou, Jean-François Emile, et al.
BMC Cancer|July 26, 2011
Open versus laparoscopically-assisted oesophagectomy for cancer: a multicentre randomised controlled phase III trial - the MIRO trialNicolas Briez, Guillaume Piessen, Franck Bonnetain, et al.
BJU International|August 13, 2018
Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancerCharlotte Fenioux, Christophe Louvet, Emilie Charton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203Jean-Pierre Gérard, Thierry Conroy, Franck Bonnetain, et al.
BMC Cancer|July 10, 2015
Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial--the PRODIGE 22--ECKINOXE trialMehdi Karoui, Anne Rullier, Alain Luciani, et al.
The Oncologist|September 28, 2011
Time to deterioration in quality of life score as a modality of longitudinal analysis in patients with breast cancerZeinab Hamidou, Tienhan S Dabakuyo, Mariette Mercier, et al.
British Journal of Cancer|July 13, 2016
Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)Dewi Vernerey, Florence Huguet, Angélique Vienot, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2012
Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trialsCarine A Bellera, Marina Pulido, Sophie Gourgou, et al.
Pageof 17

Showing results (111-120 of 161) with videos related to

Sort By:
Pageof 17
International Journal of Cancer|July 30, 2016
Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological scoreMarine Jary, Thierry Lecomte, Olivier Bouché, et al.
American Journal of Clinical Oncology|April 8, 2009
Pilot study of transarterial chemoembolization with pirarubicin and amiodarone for unresectable hepatocellular carcinomaBoris Guiu, Cédric Colin, Jean-Pierre Cercueil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2011
Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapyAziz Zaanan, Jean-François Fléjou, Jean-François Emile, et al.
BMC Cancer|July 26, 2011
Open versus laparoscopically-assisted oesophagectomy for cancer: a multicentre randomised controlled phase III trial - the MIRO trialNicolas Briez, Guillaume Piessen, Franck Bonnetain, et al.
BJU International|August 13, 2018
Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancerCharlotte Fenioux, Christophe Louvet, Emilie Charton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203Jean-Pierre Gérard, Thierry Conroy, Franck Bonnetain, et al.
BMC Cancer|July 10, 2015
Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial--the PRODIGE 22--ECKINOXE trialMehdi Karoui, Anne Rullier, Alain Luciani, et al.
The Oncologist|September 28, 2011
Time to deterioration in quality of life score as a modality of longitudinal analysis in patients with breast cancerZeinab Hamidou, Tienhan S Dabakuyo, Mariette Mercier, et al.
British Journal of Cancer|July 13, 2016
Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)Dewi Vernerey, Florence Huguet, Angélique Vienot, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2012
Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trialsCarine A Bellera, Marina Pulido, Sophie Gourgou, et al.
Pageof 17